NCT03391765
Brief summary
The purpose of this study is to assess the long-term safety and efficacy of an active drug in subjects with progressive supranuclear palsy (PSP). In a subset of participants at participating sites, participants will be assigned digital sensor BioStamp to assess body position and gait.
Interventional study
- 1
- 2
- 3
- 4
Would you like to know more about this trial?
|
Please note, participation in the clinical trial is open to patients with the disease or condition under investigation. |
Age:
40 Years and older.
Inclusion Criteria:
- Participant completed the 52-week treatment period in Study M15-562 (NCT02985879)
- In the opinion of the investigator, the participant was compliant during participation
in Study M15-562 (NCT02985879)
- Participant has an identified, reliable, study partner (e.g., caregiver, family
member, social worker, or friend)
Exclusion Criteria:
- Participants who weigh less than 44 kg (97 lbs) at the time of study entry
- Any contraindication or inability to tolerate brain magnetic resonance imaging (MRI)
- Participant has any significant change in his/her medical condition that could
interfere with the subject's participation in the study, could place the subject at
increased risk, or could confound interpretation of study results
- More than 8 weeks have elapsed since the participant received his/her last dose of
study drug in Study M15-562 (NCT02985879)
- Participant is considered by the investigator, for any reason, to be an unsuitable
candidate to receive ABBV-8E12 or the participant is considered by the investigator to
be unable or unlikely to comply with the dosing schedule or study evaluations
